CHF 0.00
In stock
SYN-1081-M0011 mgCHF 114.00
SYN-1081-M0055 mgCHF 184.00
SYN-1081-M01010 mgCHF 284.00
SYN-1081-M05050 mgCHF 922.00
SYN-1081-M100100 mgINQ
More Information
Product Details
Synonyms SNS314
Product Type Chemical
Formula C18H15ClN6OS2
MW 430.9
CAS 1057249-41-8
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO or ethanol.
Declaration Manufactured by SynKinase.
Other Product Data Target: Aurora A | Kinase Group: Other | Substrate: Serine-Threonine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Aurora kinases constitute a family of serine-threonine kinases that are strongly associated with cancer. Aurora A and B are essential in mitosis. Perturbation of their activity leads to multiple defects in mitosis including aberrant centrosome duplication, misalignment of chromosomes, inhibition of cytokinesis, and disruption of the spindle checkpoint. The role of Aurora C is unclear; however, Aurora C can complement Aurora B kinase activity in mitosis. SNS-314 is an ATP-competitive, selective, and potent nanomolar inhibitor of aurora kinases in vitro. A cocrystal structure of SNS-314 with Aurora A confirms that SNS-314 engages the purine-binding pocket of Aurora. SNS-314 inhibits cellular proliferation in the HCT116 colorectal carcinoma cell line with an EC50 of ~5nM. Analysis of DNA content and indirect immunofluoresence demonstrates that SNS-314 induces defects in cytokinesis and spindle checkpoint that are consistent with Aurora kinase inhibition. Phosphorylation of Histone H3 on serine 10, a known Aurora B cellular target, is inhibited with an EC50 of ~9nM following treatment of cells with SNS-314. Administration of SNS-314 to HCT116 tumor bearing mice potently suppresses tumor growth. Analysis of SNS-314 treated tumors confirms that the anti-tumor activity is consistent with Aurora kinase inhibition. SNS-314 is a potent small-molecule inhibitor of Aurora kinase that is being developed as a novel anti-cancer therapeutic agent.
Product References
  1. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model: E.C. VanderPorten, et al.; Mol. Cancer Ther. 8, 930 (2009)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.